Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

No increased risk for new-onset T2D was found after mild SARS-CoV-2 infection in a multiethnic Asian cohort during the ...

COVID-19 has continued to alarm public health, and although several therapeutics and vaccines have been developed, the development of effective vaccines or antibodies is challenging due to mutations ...

Pregnant women who contract SARS-CoV-2 may have a lower risk of developing Long COVID than matched non-pregnant women.

The second infection was also tied to a 50% or greater increase in several specific long-COVID conditions, including ...

More than five years since COVID was declared a pandemic, we're still facing the regular emergence of new variants of the ...

The latest variant on the rise is LP.8.1. It’s increasing in Australia, making up close to one in five COVID cases in New ...

So far this year, Australia has recorded close to 45,000 new COVID-19 cases, while around 260 people are currently in ...

COVID-19 as a whole is still a major national and international health concern. So far this year, there have been close to 45 ...